Amgen collaborating with Adaptive to create COVID-19 medicine
Thousand Oaks-based biotech giant Amgen announced April 2 that it is collaborating with Adaptive Biotechnologies to discover and develop antibodies that can be used to prevent or treat COVID-19. Amgen shares gained 4 percent to $205.88 as of 10:25 a.m and Adaptive’s stock was up 0.8 percent to $27.72. Year-to-date, Amgen’s stock is down 14 Read More →
Thousand Oaks buildings being redeveloped for biotech labs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
T.O. industrial building sold for biotech lab redevelopment
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara burned cash but raised more during fourth quarter
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen issues $5 billion in debt securities
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dyve, Arcutis launch clinical studies of dermatology products
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks biotech Amgen ponders acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
